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Abstract
The Ras/mitogen-activated protein kinase (MAPK) pathway is considered to be a positive regulator of tumor initi-
ation, progression, and maintenance. This study reports an opposite finding: we have found strong evidence that
the MAPK pathway is inhibited in a subset of adenoid cystic carcinomas (ACCs) of the salivary glands. ACC tumors
consistently overexpress the receptor tyrosine kinase (RTK) c-Kit, which has been considered a therapeutic target.
We performed mutational analysis of the c-Kit gene (KIT ) in 17 cases of ACC and found that 2 cases of ACC had
distinct missense mutations in KIT at both the genomic DNA and messenger RNA levels. These mutations caused
G664R and R796G amino acid substitutions in the kinase domains. Surprisingly, the mutations were functionally
inactive in cultured cells. We observed a significant reduction of MAPK (ERK1/2) activity in tumor cells, as assessed
by immunohistochemistry. We performed further mutational analysis of the downstream effectors in the c-Kit
pathway in the genes HRAS, KRAS, NRAS, BRAF, PIK3CA, and PTEN. This analysis revealed that two ACC tumors
without KIT mutations had missense mutations in either KRAS or BRAF, causing S17N K-Ras and V590I B-Raf mu-
tants, respectively. Our functional analysis showed that proteins with these mutations were also inactive in cul-
tured cells. This is the first time that MAPK activity from the RTK signaling has been shown to be inhibited by gene
mutations during tumor development. Because ACC seems to proliferate despite inactivation of the c-Kit signaling
pathway, we suggest that selective inhibition of c-Kit is probably not a suitable treatment strategy for ACC.
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Introduction
Adenoid cystic carcinoma (ACC) is the second most common malig-
nant neoplasm of salivary glands [1–3]. It arises in the major and
the minor salivary glands as well as in the seromucinous glands of
the upper respiratory tract. ACC is composed of a bipopulation of
duct-type epithelial cells and myoepithelial cells and forms three dis-
tinctive microscopic patterns. They are categorized as predominantly
tubular, cribriform, or solid types. Among the three subtypes, the
solid form often has the highest recurrence rate and the worst long-
term prognosis.
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ACC grows slowly with wide anatomic extension, although it in-
frequently metastasizes to regional lymph nodes. Advanced tumors
can invade nerves, causing pain, numbness, and/or paralysis, with ex-
tension into vital structures, including the brain. Although short-term
survival is high, almost half of patients develop distant metastases
or succumb to local recurrences within 10 to 20 years of diagnosis.
Metastases occur most commonly in the lungs and less commonly
in the liver and bone. Unfortunately, even patients with good local
control can develop distant metastases more than 10 years after initial
therapy. As a result, ACC is considered by some to be a systemic dis-
ease with an unpredictable and unrelenting clinical course. Therapy is
typically surgical resection with postoperative radiation [2,4,5]. Con-
ventional chemotherapy has a poorly defined role in the treatment of
ACC, and the lack of successful systemic therapy is a further obstacle
to improving outcomes.
There is an increased interest in determining the molecular abnor-
malities that underpin ACC, with the hope that doing so will lead
to the discovery of an effective targeted therapy [5]. One possibility
involves transmembrane receptor tyrosine kinases (RTKs). RTKs play
a critical role in initiation and development of many tumor types, in-
cluding those arising in the head and neck, and offer potential as ther-
apeutic targets in ACC [6].
C-Kit (also known as CD117) is an RTK encoded by the KIT
gene. It is a member of the platelet-derived growth factor receptor
(PDGFR) family that exhibits five Ig-like domains in its extracellular
region [7,8]. C-Kit was originally identified as an oncoprotein encoded
by a feline sarcoma virus. It is activated by receptor dimerization on
stimulation by its ligand, stem cell factor (SCF) [9]. Once c-Kit is ac-
tivated, diverse intracellular responses are induced through major
signaling cascades such as the phosphoinositide-3 kinase (PI3K/Akt)
and mitogen-activated protein kinase (MAPK) pathways [10–12].
The latter process is activated in the sequence of Ras, Raf (also known
as MAPKKK), MEK1/2 (MAPKK), and ERK1/2 (classic MAPK)
[13,14]. Thus, c-Kit regulates cell survival and growth control through
the PI3K/Akt and MAPK signaling pathways and contributes to nu-
merous life phenomena. For example, c-Kit cell signaling plays an
important role in stimulating the formation of many types of blood
and other cells, including melanocytes, germ cells, and the interstitial
cells of Cajal, which mediate intestinal motility [6].
Recent studies have demonstrated that almost all ACCs show over-
expression of c-Kit [2,3,15,16]. In contrast, c-Kit expression is seldom
increased in other head and neck tumors. For this reason, c-Kit ex-
pression is often used as a diagnostic pathology aid for ACC. In addi-
tion, c-Kit might play important roles in the oncogenesis of ACC and
in tumor maintenance. It could also be a therapeutic molecular tar-
get in ACC [5,17,18] and other conditions. For instance, in some leu-
kemias and gastrointestinal tumors (GISTs), inhibiting c-Kit activity
using imatinib mesylate (Gleevec) has proven to be clinically effective
treatment modality [19].
Unfortunately, conflicting data exist regarding the impact of c-Kit
inhibition on ACC. Two recent case reports have suggested that c-Kit
targeted therapy inhibits the growth of ACC [20,21]. In contrast, a
phase 2 clinical trial using imatinib found no objective responses in
27 patients with ACC despite high c-Kit expression levels in their
tumors [5,17,18]. These results suggest that reducing c-Kit ex-
pression using imatinib may not be sufficient to achieve a clinical
response in ACC. Moreover, sensitivity to the compound might de-
pend on the presence of c-Kit mutations and/or the incidence of
an autocrine-activating loop by its ligand SCF. The objective of




Seventeen tumor samples of ACC were retrieved from the Univer-
sity of California, San Francisco (UCSF) Oral Pathology and Ana-
tomic Pathology archives (Table 1) following UCSF guidelines for
obtaining and handling human tissue. Slides were reviewed to deter-
mine the suitability of tissues for genomic analysis and for tumor
grading into tubular, cribriform, and solid types [1].
Immunohistochemistry
To examine c-Kit or active ERK1/2 protein expression in ACC
tumors, immunohistochemistry (IHC) was performed on unstained
sections using antibody-based staining kits for 104D2 c-Kit (Dako,
Carpinteria, CA) or D13.14.4E phospho-p44/42 MAPK (Cell Sig-
naling Technology, Danvers, MA [CST]) [16]. The detailed pro-
cedure for staining has been described [22]. Positive c-Kit protein
expression was defined as membrane staining of at least 25% of
tumor cells.
Mutation Analysis
Genomic DNA or messenger RNA (mRNA) from each case of ACC
was isolated from formalin-fixed, paraffin-embedded (FFPE) tissue sec-
tions using a QIAampDNA FFPE Tissue kit (Qiagen, Valencia, CA) or
a PureLink FFPE RNA isolation kit (Invitrogen, Carlsbad, CA). DNA
samples were amplified by polymerase chain reaction (PCR) with the
primer sets listed in Table 2 and proofreading capability platinum Taq
DNA polymerase (Invitrogen). mRNA samples were used for first-
strand complementary DNA (cDNA) synthesis after PCR amplifi-
cation with the primer sets listed in Table 3, using an AccuScript
high-fidelity RT-PCR kit (Agilent Technology, Santa Clara, CA). Di-
rect sequencing of the PCR products was subsequently performed at
the UCSF Genomics Core Facility using ABI BigDye v3.1 dye ter-
minator sequencing chemistry (Applied Biosystems, Carlsbad, CA),
an ABI PRISM 3730xl capillary DNA analyzer (Applied Biosystems)
and Mutation Surveyor v2.5 (SoftGenetics, State College, PA). Each
observed mutation was confirmed by at least three different sets of
mutation analyses.
Table 1. Clinicopathologic Features of Sporadic ACC Samples Used in This Study.
Case Sex Age (years) Tumor Site Histologic Diagnosis c-Kit Expression
1 F 61 Palate Cribriform +
2 M 51 Palate Cribriform +
3 F 74 Palate Tubular + cribriform +
4 M 57 Palate Tubular +
5 F 51 Palate Solid + cribriform +
6 F 45 Maxilla Solid +
7 F 72 Maxilla Tubular + cribriform +
8 F 43 Parotid gland Cribriform +
9 F 48 Parotid gland Tubular +
10 F 69 Face Cribriform +
11 F 75 Floor of mouse Tubular + cribriform +
12 F 73 Lip Cribriform −
13 F 52 Paranasal sinus Tubular + cribriform −
14 M 39 Pterygopalatine fossa Tubular +
15 F 77 Submandibular gland Cribriform +
16 F 62 Tongue Cribriform +
17 F 72 Trachea Tubular +
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DNA Plasmids and Site-Directed Mutagenesis
Wild-type human c-Kit cDNA (Origene, Rockville, MD) was sub-
cloned into a pcDNA3.1 vector (Invitrogen). K-Ras cDNA (Origene)
was subcloned into an N-terminal Myc epitope-tagged pcDNA3.1
expression vector [23]. The Myc epitope-tagged wild-type B-Raf
pcDNA3.1 expression vector has been described [13]. C-Kit, K-Ras,
and B-Raf mutants were generated with a QuickChange site-directed
mutagenesis kit (Agilent Technologies). All mutations were verified
by sequencing at the UCSF Genomics Core Facility.
Chemical, Cell Line, and Transfection
Human recombinant SCF was purchased from CST. Human em-
bryonic kidney (HEK) 293T cells and African green monkey kidney
fibroblast-like COS-7 cells were obtained from the American Type
Culture Collection (ATCC, Manassas, VA). Cells were cultured in
RPMI 1640 medium (Invitrogen) containing 10% fetal bovine serum
(PAA, New Bedford, MA). They were maintained in a 5% CO2 in-
cubator at 37 C. TransIT-LT1 (Mirus, Madison, WI) was used for tran-
sient transfections.
Western Blot Analysis
Total cellular protein was prepared using cell lysis buffer (CST).
Equal amounts of total protein were resolved by SDS-PAGE. Western
blots were developed by enhanced chemiluminescence (GE Healthcare
Life Sciences, Piscataway, NJ). The following primary and secondary
antibodies were used: phospho–c-Kit tyrosine 721 (3391; CST), c-Kit
(AB81; CST), phospho–C-Raf serine 289/296/301 (9431; CST),
C-Raf (610151; BD Biosciences, San Jose, CA), phospho–MEK1/2
serine 218/222 or serine 222/226 (9121; CST), MEK1/2 (9122;
CST), phospho–ERK1/2 (E-4; Santa Cruz Biotech [SCB], Santa Cruz,
CA), ERK1/2 (K-23; SCB), Myc (A-14 HRP-conjugated; SCB),
β-actin–HRP (Sigma, St. Louis, MO), antimouse IgG HRP (7076;
CST), and antirabbit IgG HRP (7074; CST).
Results
Characteristics of Tumors
We identified 17 tumor samples that fulfilled the criteria for ACC
in the UCSF Oral Pathology and Anatomic Pathology archives. Table 1
summarizes the clinical attributes of their donor patients. All tumors
had arisen sporadically. Fourteen tumors occurred in women, and
three tumors occurred in men. The mean age at presentation was
60 years (range, 39-77 years). All tumors arose at the following sites:
palate (five tumors), maxilla (two tumors), parotid gland (two tumors),
and one each for the following sites: face, floor of mouth, lip, para-
nasal sinus, pterygopalatine fossa, submandibular gland, tongue, and
trachea. The tumors were graded into the following morphologic pat-
terns: cribriform (seven tumors), tubular (four tumors), solid (one tu-
mor), combined cribriform and tubular (four tumors), and combined
solid and tubular (one tumor).
Expression of c-Kit Was Elevated in Sporadic ACC Tumors
Given that recent studies have demonstrated that almost all ACC
tumors show increased expression of c-Kit, we performed IHC for
this protein on tumor sample sections using a c-Kit/CD117 antibody.
IHCwas assessed by scoring the presence or absence of positively stained
cells. Positive cases were defined as membrane staining in at least 25%
Table 3. Oligonucleotide Primer Sequences for Detecting KITmRNA.
Genes Targeted Codon Forward Primer Sequence (5′ to 3′) Reverse Primer Sequence (5′ to 3′) Expected PCR Product Size (bp)
KIT 664 GAGGCAACTGCTTATGGCTTA TGTCGGCCTTGGTTGGGACA 400
KIT 796 TGTCCCAACCAAGGCCGACA TGCTTTCAGGTGCCATCCACTTCA 329
Table 2. Oligonucleotide Primer Sequences for Detecting KIT, HRAS, KRAS, NRAS, BRAF, PIK3CA, and PTEN.
Genes Exon Forward Primer Sequence (5′ to 3′) Reverse Primer Sequence (5′ to 3′) Expected PCR Product Size (bp)
KIT 9 TAAAAGTATGCCACATCCCAAG CATGGTCAATGTTGGAATGAAC 368
KIT 11 TCCAGAGTGCTCTAATGAC AGGTGGAACAAAACAAAGG 292
KIT 13 AAGATGCTCAAGCGTAAGTTC AAGCAGTTTATAATCTAGCATTGCC 302
KIT 17 GTGAACATCATTCAAGGCGT CCTTTGCAGGACTGTCAAGCA 336
HRAS 1 TCTAGAGGAAGCAGGAGACAGG CTTTTCCCATCACTGGGTCAT 515
HRAS 2 GAGTCCTTCACCCGTTTGATCT CCCTGTCTCCTGCTTCCTCTA 519
KRAS 1 GCACAGAGAGTGAACATCATGG CATTTTTCTTAAGCGTCGATGG 574
KRAS 2 ACAGAAGGCTGTGGAGTCAAAC TCATCTTTGGAGCAGGAACAAT 574
NRAS 1 GGACAGGTTTTAGAAACTTCAGCA GGGAGTAATAGGAAGGGGGATT 590
NRAS 2 CCAAGTCATTCCCAGTAGCAAG TTTGAGGGACAAACCAGATAGG 568
BRAF 11 TGAGGACTAGTTAACCTGGAGGA TTTTTCCATCCTAATATTGACTTCAG 581
BRAF 15 TTTTTCAACAGGGTACACAGAACA GCCCCAAAAATCTTAAAAGCAG 745
PIK3CA 1 GCCTAATCAAGTCAAACTATGGAAA TCTAAGTCATCCCACAAATGACA 769
PIK3CA 9 TGGTTCTTTCCTGTCTCTGAAAA GCATTTAATGTGCCAACTACCAA 521
PIK3CA 20 GCTTTGTCTACGAAAGCCTCTCT GCAATAACAGCCTTTGTTGTGTC 793
PTEN 2 TCAATTTTGGGGTTTTGTTTTG ACTGTATCCCCCTGAAGTCCAT 563
PTEN 3 TCTGAAAAGCTCTGGTTTTACTTCA ATATGGGCTAGATGCCAAGTCA 547
PTEN 4 TGGCATCACAAGTTTTTAAGCA AGACCAACTGCCTCAAATAGTAGG 600
PTEN 5 GGGGAAAATAATACCTGGCTTC GAAGCTCTACTGGACAGCATAGTG 798
PTEN 6 CGCTGTTGTGACCTTTGAATAA ATTGCTTTTGGCTTCTTTAGCC 589
PTEN 7 TTGAAGGTTCAAACTGGAGAAAA AATGTCTCACCAATGCCAGAGT 516
PTEN 8 CATGTGAATGAAAATGCAACAGA TGTTACTGCTACGTAAACACTGCTTC 581
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of tumor cells. Table 1 shows the results of this study. We identified
expression of c-Kit in 15 (88%) of 17 tumors. No immunoreactivity
was observed in adjacent normal salivary gland tissue, suggesting that
c-Kit immunoreaction was specific.
Two ACC Tumors Demonstrated Heterogeneous KIT Missense
Mutations That Caused Distinct Amino Acid Changes in the
c-Kit Protein
We searched for genomic alterations in KIT in our 17 ACC tumor
samples. Similar investigations have been conducted by others specif-
ically in exons 11 and 17 of c-Kit in the ACC tumors [15]. We in-
cluded other important functional domains such as exons 9 and 13
within c-Kit in our mutation analysis. Genomic DNA was isolated
from FFPE tissue sections. DNA samples were amplified by PCR
with primer sets independently designed to amplify specific sized
products of exons 9, 11, 13, and 17 of KIT (Table 2). These exons
encode domains for dimerization (exon 9), the juxtamembrane re-
gion (exon 11), or protein kinase activity (exons 13 and 17) [24].
We chose them because gain-of-function mutations are frequently
found in these regions of KIT in other neoplasms, such as in acute
myeloid leukemia, GIST, mastocytosis, and seminomas [25]. We per-
formed direct sequencing of each exon’s PCR product. Each observed
mutation was confirmed by at least three different sets of mutation
analyses. We identified two heterogeneous missense mutations in
KIT (Table 4). Mutations were identified at a lower frequency than
in other neoplasms, but they were specific and nonrandom: no frame-
shift, nonsense, synonymous missense, or splice mutations were de-
tected in the cohort of sporadic ACC tumor specimens. Two ACC
tumors (cases 9 and 10) had nucleotide (nt) switches. Specifically, they
were nt1990G→ A in exon 13 in case 9 (Figure 1A) and nt2386A→
G in exon 17 in case 10 (Figure 1B). The predicted missense sub-
stitutions were arginine for glycine 664 (G664R) and glycine for argi-
nine 796 (R796G) in the protein kinase domain. These mutations
were found in highly conserved residues in the intracellular kinase
domain of the gene, suggesting that they should affect the protein
kinase activities of the ACC c-Kit mutants.
Because cases 9 and 10 were heterozygous for these c-Kit muta-
tions at the genomic DNA level (Figure 1, A and B), we investigated
whether the c-Kit protein expression noted in Table 1 was from the
mutant allele. We performed reverse transcription (RT)–PCR and
subsequent direct sequencing of the products to address the question
(Figure 1, C and D). mRNA was isolated from FFPE tissue sections.
Next, first-strand cDNA was synthesized from each sample. Specific-
sized products of the c-Kit gene, which contained either codon 664
or 796, were independently amplified by PCR with the primer sets
indicated in Table 3. We performed direct sequencing of these PCR
products. Each observed mutation was confirmed by at least three
different RT-PCR assays. Case 9 expressed both the wild-type and
G664R mutant forms of c-Kit (Figure 1C ), suggesting that tumor
cells in this sample might consist of a heterogenous population. In
contrast, we found that case 10 expressed the R796G mutant form
but not the wild-type form (Figure 1D), indicating that most of the
cells were homogeneous and had the same R786G c-Kit mutation.
Taken together, we concluded that the elevated c-Kit protein ex-
pression found in cases 9 and 10 was indeed from the mutant allele.
We reasoned that, if our ACC c-Kit mutants functioned actively,
c-Kit might play a role in the development of at least some subsets
of ACC and that patients may benefit from c-Kit targeted therapy
with imatinib.
ACC c-Kit Mutations Are Inactive
To explore the functional consequences of these mutations, we in-
troduced expression vectors containing G664R and R796G mutant
forms of c-Kit into HEK 293T cells. HEK 293T cells were chosen
because they barely express endogenous c-Kit and because widely
used cell lines thought to be ACC cells have recently been shown
to have been replaced with other cells because of cross-contamination
and misidentification [3].
Twenty-four hours later, we assessed the cells’ ability to autophos-
phorylate at tyrosine 721 [13,25]. Tyrosine 721 is located in the ki-
nase insert region of the catalytic domain and its phosphorylation is
essential for c-Kit activation [25]. Phosphorylation status was deter-
mined by Western blot analysis (Figure 2A).
We compared the activities of our ACC mutants with wild-type
c-Kit and two other variants. The variant forms included K623M
Table 4. Summary of Mutation Analysis in Sporadic ACC.
Case Genes
KIT HRAS KRAS NRAS BRAF PIK3CA PTEN
1 — — — — N/A — —
2 — nt81T → C (H27H) nt50G → A (S17N) — — — —
3 — — — — — — —
4 — — — — — nt2994C → T (F998F) —
5 — nt81T → C (H27H) — — — — —
6 — nt81T → C (H27H) — — — — —
7 — — — — — — —
8 — — — — — — —
9 nt1990G → A (G664R) — — — — — —
10 nt2386A → G (R796G) — — N/A N/A N/A N/A
11 — nt81T → C (H27H) — — nt1768G → A (V590I) — —
12 — nt81T → C (H27H) — N/A — nt318C → A (G106G) —
13 — — — — — — —
14 — nt81T → C (H27H) — — — — —
15 — — — nt57G → A (L19L) — — —
16 — nt81T → C (H27H) — — — N/A —
17 — nt81T → C (H27H) — — — — —
Four missense mutations in three different genes within the c-Kit RTK signaling pathway, namely KIT, KRAS, and BRAF, were found. All of these ACC mutations caused amino acid changes in the
resultant proteins.
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Figure 2. ACC c-Kit mutations are inactive and caused substantial reduction of MAPK activity in tumor cells. (A, B) HEK 293T cells were
plated into six-well plates. Twenty-four hours later, subconfluent cells were transfected with 2 μg each of expression vectors containing
the various c-Kit mutants. (A) After 24 hours of incubation, the cells were harvested. (B) After 24 hours of incubation, the cells were
serum-starved for 16 hours with medium containing 0.5% fetal bovine serum. Cultures were incubated for 15 minutes in the presence (+)
or absence (−) of 50 ng/ml SCF before harvesting. Western blot analysis was performed using antibodies against phosphorylation specific
c-Kit (P-c-Kit), c-Kit specific for the c-Kit variants, and β-actin as a loading control. The following c-Kit vectors were independently trans-
fected: Empty (pcDNA 3.1) wild-type, K623M (catalytically inactive), D816V (constitutively active), and G664R and R796G (found in ACC).
(C, D) IHC was performed on unstained sections using antibodies to Kit (left panels) or phospho-p44/42 MAPK (right panels). Phosphor-
ylated forms of ERK1/2 (right panels) were barely detectable in both cases despite strong expression of c-Kit (left panels).
Figure 1. KIT mutations in tumor samples from sporadic ACC. (A) Genomic DNA electropherograms of case 8 (left) and case 9 (right) are
shown. They identify the KIT missense mutation in exon 13. Case 8 has a wild-type (WT) sequence. Case 9 has nucleotide (nt) switches,
specifically nt1990G → A in exon 13, with a predicted missense substitution of arginine for glycine 664 (G664R). The first and second
nucleotides for codon 664 are highlighted with underlines. The third nucleotide is located in a different exon. (B) Genomic DNA electro-
pherograms of case 8 (left) and case 10 (right) are shown, identifying the KIT missense mutation in exon 17. Case 8 has a WT sequence.
Case 10 has an nt2386A → G transition in exon 17, with a predicted missense substitution of glycine for arginine 796 (R796G). Triplet
nucleotides at codon 796 are marked with underlines. (C) RT-PCR products electropherograms of case 8 (left) and case 9 (right). Case 8 has
a wild-type (WT) sequence. Case 9 has the KIT missense mutation in codon 664. Triplet nucleotides for codon 664 are highlighted with
underlines. (D) RT-PCR products electropherograms of case 8 (left) and case 10 (right) RT-PCR products are shown. Case 8 has a wild-type
(WT) sequence. Case 10 has the KIT missense mutation in codon 796. Triplet nucleotides for codon 796 are highlighted with underlines.
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(methionine substitution for the catalytic lysine at residue 623) and
D816V (substitution of valine for aspartic acid at residue 816).
K623M is catalytically inactive, and D816V is constitutively active.
D816V c-Kit is often found in different types of human malignancies,
including acute myeloid leukemia, mastocytosis, seminomas, lympho-
mas, GIST, and teratomas [26,27]. We observed significant autophos-
phorylation at tyrosine 721 in the cells with D816V c-Kit (Figure 2A,
lane 6; P-c-Kit). In contrast, K623M c-Kit was not phosphorylated at
tyrosine 721, as expected (lane 3). Surprisingly, the phosphorylation of
both ACC mutants was much lower than wild-type, and they seemed
to be kinase-inactivated (lanes 4 and 5). Similar profiles were obtained
when the experiments were performed in COS-7 cells (not shown).
We next examined whether our ACC c-Kit mutants could be ac-
tivated in response to stimulation with SCF, the c-Kit ligand (Fig-
ure 2B). SCF is the sole activator of c-Kit, and the ACC mutants
might be activated in the presence of an autocrine-activating loop
by SCF. Cells were serum-starved for 16 hours after transfection
and then cultured with (+) or without (−) SCF for 15 minutes before
harvesting [28]. We found constitutive phosphorylation of c-Kit in the
cells transfected with D816V (lanes 11 and 12). Autophosphorylation
was observed with or without SCF. No activation was observed in the
samples transfected with K623M c-Kit (lanes 5 and 6 ). SCF increased
phosphorylation of wild-type c-Kit (lanes 3 and 4 ). In contrast, we did
not see an increase of phosphorylated c-Kit protein in the samples
transfected with the ACC mutant R796G (lanes 9 and 10). There
was a slight increase in the other mutant form (G664R; lanes 7 and
8), but the level of activation was much lower than that of wild-type
c-Kit. Similar data were obtained in COS-7 cells (not shown).
These results suggested that ACC c-Kit mutants had lost most
(G664R) or all (R796G) protein kinase activity. Taken together,
we concluded that c-Kit is inactive in the ACC mutants.
ACC c-Kit Mutations Reduced MAPK Activity in Tumor Cells
To determine the biological significance of these c-Kit mutations
in downstream effectors—particularly in the MAPK signaling pathway
in ACC tumors—we performed IHC on tumor sample sections using
a phosphorylation-specific ERK1/2 antibody (Figure 2, C and D).
We included a positive control from a breast cancer sample to con-
firm whether our protocol and procedure worked properly (data not
shown). As expected, phosphorylated forms of ERK1/2 were barely
detectable in both cases (right panels), despite the fact that both tu-
mors strongly expressed c-Kit (left panels). Positive staining was found
in only 1% of the cells in case 9, whereas almost no immunoreactiv-
ity was observed in case 10: some cells stained weakly, but no strong
staining was observed. We concluded that c-Kit mutations caused
substantially reduced MAPK activity in ACC tumor cells.
Two ACC Tumors without KIT Mutations Had Missense
Mutations in KRAS and BRAF, Downstream Effectors of c-Kit
We performed further mutation analysis in the components of the
c-Kit downstream signaling pathways, including the Ras/MAPK and
PI3K/Akt cascades. The PI3K/Akt and MAPK signaling pathways are
important for tumor progression in several human cancers [13,14]. In
fact, mutations in the downstream signaling elements often amplify
the transmission of messages from RTKs.
Because oncogenic mutations are frequently found inHRAS, KRAS,
NRAS, and BRAF in the MAPK pathway as well as in PIK3CA and
PTEN in the PI3K/Akt cascade, we searched for mutations in these
genes [14]. Table 2 shows primer sets used to detect oncogenic muta-
tions in these genes and our exons of focus. These exons were chosen
because most gain-of-function mutations in HRAS, KRAS, NRAS,
BRAF, and PIK3CA are frequently found in them in a variety of neo-
plasms, as are loss-of-function mutations in PTEN [29–31]. Table 4
summarizes our results. There were amino acid changes in two ACC
tumors: case 2 (K-Ras) and case 11 (B-Raf ). There was a missense
substitution of asparagine for serine 17 (S17N) of K-Ras (nt50G →
A transition in exon 1; Figure 3A) and an isoleucine-for-valine 590 sub-
stitution (V590I) in the protein kinase domain of B-Raf (nt1768A→
G in exon 15; Figure 3B).
No amino acid change, frameshift, nonsense, or splice mutations
were detected in HRAS, NRAS, PIK3CA, and PTEN in the cohort
of ACC tumors. Eight ACC tumors, however, had a synonymous sin-
gle nucleotide polymorphism (SNP) in HRAS. This SNP was rs12628
(nt81T→ C); it was found in patients 2, 5, 6, 11, 12, 14, 16, and 17.
There was one synonymous SNP (nt57G → A) in NRAS in case 15,
and there were two synonymous SNPs (nt2994C→ Tand nt318C→
A) in PIK3CA in cases 4 and 12. These synonymous mutations do not
change the amino acid sequence of the gene products of HRAS, NRAS,
or PIK3CA, and they are therefore functionally identical to their wild-
type counterparts.
Because c-Kit protein was expressed in the tumors harboring K-Ras
and B-Raf mutations (cases 2 and 11 in Table 1), we hypothesized that
thesemutantsmust render c-Kit–MAPK signaling by their loss or reduced
function. Alternatively, they might antagonize the gene product of the
wild-type allele. Thus, we expected that S17N K-Ras and V590I B-Raf
would have similar functional consequences in the signaling pathway.
ACC K-Ras and B-Raf Mutations Are Inactive
or Kinase-Impaired
The ACC K-Ras mutant form S17N was particularly interesting be-
cause it has not been reported in human cancer and genetic disease.
Nonetheless, it is well known as a dominant-negative form of the pro-
tein, and has been widely used as a tool to study the Ras/MAPK
signaling pathway [32,33]. The asparagine substitution for serine 17
dramatically reduces Ras’s affinity for GTP without affecting its affinity
for GDP. Thus, expression of S17N K-Ras can block exchange factor–
mediated activation of endogenous K-Ras.
The functional significance of the ACC B-Raf mutant V590I is un-
known, although it has been found in one case of childhood acute
lymphoblastic leukemia [34]. This leukemia patient simultaneously
carried an N-Ras activated mutant.
We examined the functional consequences of the mutations in K-
Ras and B-Raf in the ACC samples (Figure 3, C and D). To do so,
we introduced expression vectors containing S17N K-Ras and V590I
B-Raf into HEK 293T cells and assessed the effects of endogenous
activation within the MAPK signaling pathway [13]. Activation was
assessed by Western blot analysis of the phosphorylation status of the
molecules (see P-C-Raf in Figure 3C and P-MEK1/2, P-ERK1/2 in
Figure 3, C and D).
We compared the activities of S17N K-Ras with wild-type and
G12V (substitution of valine for glycine 12 of K-Ras). We also com-
pared the activity of V590I B-Raf with wild-type B-Raf, K483M
(methionine substitution for the catalytic lysine 483) and V600E (sub-
station of glutamine for valine 600). G12V K-Ras and V600E B-Raf
are catalytically active; K483M B-Raf is inactive. K-Ras is commonly
mutated in pancreatic and colorectal cancers, and the G12V mutation
is its most frequently observed mutation in these tumors [29,35,36].
Conversely, theV600EB-Rafmutation occurs at a high rate in numerous
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cancers. This mutation accounts for more than 90% of BRAF muta-
tions [37].
Figure 3C shows constitutive activation of C-Raf and MEK1/2
with consequent induction of ERK1/2 activities in the sample trans-
fected with G12V K-Ras (lane 4). In contrast, wild-type and S17N
K-Ras failed to stimulate the MAPK signaling cascade (lanes 2 and 3),
suggesting that the S17N is inactive. Similar profiles were obtained
when the experiments were performed in COS-7 cells (not shown).
Likewise, we observed that K483M B-Raf hardly activated its
downstream effectors MEK1/2 and ERK1/2 (Figure 3D, lane 3).
The V600E B-Raf mutant significantly increased activation of
MEK1/2 and ERK1/2 compared with B-Raf wild-type (lanes 2 and
5). However, the activity of our ACC B-Raf mutant V590I was lower
than that of the wild-type (lanes 2 and 4 ) [38]. Similar data were ob-
tained in COS-7 cells (not shown). We concluded that ACC K-Ras
and B-Raf mutants are inactive or kinase-impaired.
Discussion
We performed a functional genomic study of the RTK c-Kit gene
(KIT ) using 17 sporadic ACC tumor specimens. We found that two
ACC cases had distinct missense mutations in KIT (Figure 4). We then
explored the functional consequences of these mutations. Surprisingly,
they were inactive, and we observed a significant reduction of MAPK
activity in tumor cells harboring them. In addition, we observed that
two ACC tumors without KITmutations had missense mutations in
the downstream effectors KRAS or BRAF, causing kinase-inactive mu-
tant forms. This is the first time that a study has shown that MAPK
activity from RTK signaling is inhibited by gene mutations during tu-
mor development. Our results suggest that ACC is able to proliferate
despite inactivation of the RTK c-Kit signaling pathway. This mecha-
nism may explain why no objective responses were observed in the
phase 2 clinical trial of imatinib for 27 ACC patients.
Tumors generally have a number of genomic aberrations, and no sin-
gle genetic alteration is thought to be enough to cause tumor progres-
sion. Some mutations are necessary for initiating and/or developing
tumors but are not necessary for late-stage tumor maintenance [39].
Only a few of the numerous defective proteins responsible for tu-
mor maintenance might be attractive targets for drug development
[19]. In addition, anticancer drugs, which are usually low–molecular
weight organic compounds, inhibit biochemical functions rather than
enhance them. Thus, target molecules should be activated in cancer.
Recent data from mouse models of cancer have shown that even the
Figure 3. ACC K-Ras and B-Raf mutations were inactive or kinase-impaired. (A and B) KRAS and BRAF mutations were detected in spo-
radic ACC. (A) Genomic DNA electropherograms of case 8 (left) and case 2 (right) identify the KRAS missense mutation in exon 1. Case
8 has a wild-type (WT) sequence. In contrast, case 2 has a nt50G→ A transition with a predicted missense substitution of asparagine for
serine 17 (S17N). Triplet nucleotides for codon 17 are highlighted with underlines. (B) Genomic DNA electropherograms of case 8 (left)
and case 11 (right) identify the BRAF missense mutation in exon 15. Case 8 shows normal wild-type (WT) sequence. In contrast, case
11 has a nt1768A→ G change with a predicted missense substitution of isoleucine for valine 590 (V590I). Triplet nucleotides cording codon
590 are marked with underlines. (C and D) HEK 293T cells were plated into six-well plates. Twenty-four hours later, subconfluent cells
were transfected with 2 μg each of expression vectors containing the various K-Ras mutants (C) or 0.25 μg each of expression vectors
containing the various B-Raf mutants (D). After 24 hours of incubation, the cells were harvested. Western blot analysis was performed
using antibodies against phosphorylation-specific C-Raf (P-C-Raf), MEK1/2 (P-MEK1/2), p44 ERK1 and p42 ERK2 (P-ERK1/2), total C-Raf,
total MEK1/2, total ERK1/2, and β-actin. The following vectors were independently transfected: (C) Empty (pcDNA 3.1), wild-type, G12V
(constitutively active), and S17N K-Ras (found in ACC). In (D), the vectors were Empty (pcDNA 3.1), wild-type, K483M (catalytically in-
active), V600E (constitutively active), and V590I (found in ACC).
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brief interruptions of the activities of a single oncogene such as H-Ras,
K-Ras, c-Myc, and EGFR can reverse cancer [39]. There have been no
reports of reversibility of c-Kit–induced cancer in mice. Activation of
c-Kit might play an important role at some stage of ACC tumor pro-
gression. However, its expression is probably not necessary for ACC
tumor maintenance at the late stage because at least a subset of ACC
cells can proliferate despite inhibition of the c-Kit signaling pathway.
Thus, c-Kit does not seem to be a suitable therapeutic target in ACC.
Partial or complete loss of c-Kit function is associated with other
diseases. For example, piebaldism (also known as piebald trait; OMIM
172800) is an autosomal-dominant genetic disorder of melanocyte de-
velopment. It is characterized by white patches of skin and hair [40].
Piebaldism is a disorder of haploinsufficiency, in which there is loss of
function in one allele of the c-Kit proto-oncogene. Some subsets of
piebaldism, however, are attributed to distinct mutations in the zinc
finger transcription factor SNAI2 [41].
A disorder similar to human piebaldism also occurs in mice [42,43].
Spontaneous mutations at the dominant white (W ) locus of the lab-
oratory mouse are associated with defects of pigmentation (albinism;
white spotting of the skin), hematopoiesis (anemia), and germ cell
development (sterility). Affected mice have partial or complete loss of
c-Kit function. This fact highlights a significant function of c-Kit in
normal stem and progenitor cells for hematopoiesis and pigmentation.
In this study, we examined the biochemical functions of two ACC
c-Kit mutants: G664R and R796G. Interestingly, both mutations
have been reported in patients with piebaldism [40,44]. In particular,
a patient harboring the R796G c-Kit mutation had severe piebaldism
and profound sensorineural deafness [44]. The symptom seemed
much worse than in other cases of piebaldism, suggesting that the
R796G mutant must completely abolish c-Kit function and that the
added severity may be attributed to a dominant-negative effect [6]. This
observation is in accordance with our findings. The R796G c-Kit could
not be activated by SCF stimulation. Piebaldism patients do not have
a higher incidence of ACC, even if they have completely lost c-Kit
function through a R796G mutation. Thus, loss-of-function muta-
tions in c-Kit are probably not sufficient to cause ACC.
Gain-of-function mutations of c-Kit are frequently found in neo-
plasms, including GIST (OMIM 606764). GISTs are mesenchymal
tumors found in the gastrointestinal tract. They originate from the
interstitial cells of Cajal in the intestines [25]. Approximately 50% to
90% of GISTs are caused by mutations in KIT, and 10% to 35% of
GIST subsets arise due to the mutations in PDGFRA (PDGFRα)
[25,45]. Mutations in KIT and PDGFRA are mutually exclusive. Fa-
milial cases of GIST have germ line mutations, whereas patients with
sporadic disease have somatic mutations in tumor tissue. In contrast
to piebaldism, familial GIST patients often present with hyperpig-
mentation and mast cell hyperplasia [46].
GISTs are sensitive to c-Kit–targeted therapy with imatinib. Most
GISTs, however, develop resistance to this compound. After 2.5 years
of initial treatments, ∼75% of tumors did not respond to further
treatment with the drug [19,47]. This fact suggests that long-term
therapy with c-Kit targeted therapy may not be effective. To date,
there have been no reports of familial ACC or other salivary gland
tumors in GIST patients, indicating that gain-of-function mutations
in c-Kit play little role in ACC. In fact, our ACC c-Kit mutations
demonstrate loss of function.
The mechanism of c-Kit overexpression in ACC is not yet elu-
cidated. In the melanocyte, c-Kit is transcriptionally regulated by
the basic-helix-loop-helix-leucine zipper protein family of transcrip-
tion factor MITF [48]. We speculate that MITF might contribute
to c-Kit expression in ACC and could play a role for tumor prog-
ression in a similar way in pigment precursor cells. The MITF is en-
coded at microphthalmia (mi) locus in mice [49]. Mutant mice have
small eyes, show loss of pigmentation in the eye, inner ear, and skin,
and early-onset sensorineural deafness (OMIM 156845). The pheno-
type apparently associates mi mutant animals with W locus-deletion
mice. The association of MITF with c-Kit is mutual. MITF must
be phosphorylated at serine 73 and serine 409 to get full transcriptional
Figure 4. Cell signaling from the RTK c-Kit is disrupted during tumor development in a subset of salivary gland ACCs. C-Kit regulates cell
survival and growth control through the PI3K/Akt and MAPK signaling pathways. We found inactivating mutations in KIT, KRAS, and
BRAF. Because ACC can proliferate despite inactivation of c-Kit cell signaling, c-Kit must be dispensable for maintaining established
ACC tumors. This is the first time that inactivation of MAPK accompanied tumorigenesis. Our results also suggest that selective inhi-
bition of c-Kit is not a promising strategy for ACC therapeutic development.
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activity in melanocytes. This phosphorylation is mediated by an up-
stream signaling pathway from the RTK c-Kit [50]. Despite their
strong correlation in the progenitor cell melanocyte and frequent
MITF locus amplification particularly in advanced melanomas, c-Kit
expression is often lost in malignant melanoma [51]. Further studies
are necessary, but c-Kit V600E B-Raf mutations and p16Ink4a in-
activation may reduce the c-Kit requirement for MITF activation
in melanoma cells. Otherwise, c-Kit may have the properties of a
tumor-suppressor gene product in some contexts [52].
We conclude that c-Kit must be dispensable for tumor mainte-
nance in ACC and that selective c-Kit inhibition may not be a prom-
ising strategy for ACC therapeutic development. C-Kit activity may
be necessary for tumor initiation and at some stage of tumor progres-
sion, although further studies are required to answer this question.
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